Dr. Frank A Surita is a pharmacist who is specialized in Oncology in Commack, New York. Patients can reach him at 650 Commack Rd, Commack or contact him on 631-623-4107. Active license number of Dr. Frank A Surita is 037232 for Oncology in New York. Dr. Frank A Surita is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Frank A Surita speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Frank A Surita
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Male
Location:
650 Commack Rd, Commack, New York, 11725-5404
Phone:
631-623-4107
Fax:
631-864-5387
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Frank A Surita are as mentioned below.
NPI Number:
1922549369
NPI Enumeration Date:
18 Mar, 2017
NPI Last Update On:
18 Mar, 2017
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Frank A Surita are as mentioned below.
Specialization
License Number
State
Status
Oncology
037232
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
650 Commack Rd, Commack, New York
Zip:
11725-5404
Phone Number:
631-623-4107
Fax Number:
631-864-5387
Patients can reach Dr. Frank A Surita at 650 Commack Rd, Commack, New York or can call on phone at 631-623-4107.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.